A concurrent private placement of Series C non-voting convertible preferred stock in November 2025 resulted in approximately $284.9 million in gross proceeds and is expected to fund operations into 2029. With multiple programs with best-in-class potential on track to enter clinical development in 2026, the company aims to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes.
Cyborg Score Rationale
Galecto demonstrates solid positioning as a well-funded, clinical-stage biotech with a transformational acquisition (Damora) that refocused the company toward high-unmet-need blood cancers. The $284.9M private placement provides runway through 2029, enabling advancement of multiple programs. However, the company remains pre-commercial and faces typical biotech clinical development risks.
Top Insights
Strategic pivot (November 2025 to March 2026): Acquired Damora Therapeutics and rebranded to focus on mutCALR-driven myeloproliferative neoplasms (ET and MF), moving away from fibrosis/IPF programs
Well-capitalized through 2029: ~$285M private placement (November 2025) enables advancement of DMR-001 through Phase 1 proof-of-concept expected in 2027, plus DMR-002 and DMR-003 into Phase 1
Lead program DMR-001 designed to overcome limitations of current early-stage candidates and potentially establish new standard of care for ET and MF treatment
Institutional backing: Series C investors include Viking Global, Venrock Healthcare, RA Capital, Perceptive Advisors, and a16z Bio + Health, signaling market confidence in the blood cancer focus
Named Competitors
Ruxolitinib (Jakafi) — JAK inhibitor for myelofibrosis and polycythemia vera
Fedratinib (Inrebic) — JAK2/FLT3 inhibitor for myelofibrosis
Menin inhibitors — Investigational menin inhibitors for AML and MPN treatment
Recent Developments
(October 2024) Completed strategic review to focus on oncology and liver disease; acquired global rights to BRM-1420 (ENL-YEATS/FLT3 inhibitor) from Bridge Medicines
(November 2025) Completed acquisition of Damora Therapeutics for mutCALR-targeted therapies; concurrent $284.9M Series C private placement
(March 2026) Announced name change to Damora Therapeutics, signaling full organizational transition
Open the full interactive Galecto, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.